Otsuka Pharmaceuticals submits to FDA application for Torbaptan, a drug for the treatment of a genetic disease (autosomal dominant polycystic kidney (ADPKD))

This is considered to be the first drug for the treatment of a genetic disease.

Otsuka Pharmaceuticals press release, April 12, 2013

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny